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Abstract
Background: The purpose of the study was to determine the effectiveness and tolerability of
quetiapine as a maintenance treatment preventing against relapse or recurrence of acute mood
episodes in adolescent patients diagnosed with bipolar disorder.
Methods: Consenting patients meeting DSM-IV lifetime criteria for a bipolar disorder and clinically
appropriate for maintenance treatment were enrolled in a 48-week open prospective study. After
being acutely stabilized (CGI-S ≤ 3 for 4 consecutive weeks), patients were started or continued
on quetiapine and other medications were weaned off over an 8-week period. Quetiapine
monotherapy was continued for 40-weeks and other mood stabilizers or antidepressants were
added if clinically indicated. A neurocognitive test battery assessing the most reliable findings in
adult patients was administered at fixed time points throughout the study to patients and matched
controls.
Results: Of the 21 enrolled patients, 18 completed the 48-week study. Thirteen patients were able
to be maintained without relapse or recurrence in good quality remission on quetiapine
monotherapy, while 5 patients required additional medication to treat impairing residual depressive
and/or anxiety symptoms. According to symptom ratings and global functioning scores, the quality
of remission for all patients was very good.
Neurocognitive test performance over treatment was equivalent to that of a matched control
group of never ill adolescents. Quetiapine was generally well tolerated with no serious adverse
effects.
Conclusion: This study suggests that a proportion of adolescent patients diagnosed with bipolar
disorder can be successfully maintained on quetiapine monotherapy. The good quality of clinical
remission and preserved neurocognitive functioning underscores the importance of early diagnosis
and effective stabilization.
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Background
The onset of bipolar disorder in a substantial proportion
of patients occurs during adolescence as a depressive epi-
sode, and not uncommonly recurs as severe mood epi-
sodes with psychotic features [1]. The limited available
data suggests that adolescents manifesting acute manic
episodes respond in the short term to lithium [2-4], atyp-
ical antipsychotics [5,6] and/or anticonvulsants [7-9], in a
comparable way to adult patients. However, there is virtu-
ally no information with regard to the long-term effective-
ness of pharmacological treatment in preventing relapse
or recurrence of mood episodes (either depressive or
manic) in adolescent bipolar patients [10,11].
The deficit of information regarding effective mainte-
nance treatment is concerning. Adolescence is a critical
developmental period for the acquisition of academic and
vocational skills, mastery of separation and individuation
and for the development of interpersonal relationships.
There is evidence of a substantial benefit of early interven-
tion for patients with psychotic disorders [12,13], data
linking burden of illness effects in bipolar youth to a per-
sonal history of psychosis [14] and an emerging argument
that more resources should be focused on stabilization as
early in the course as possible [15]. Through successful
stabilization early in the illness perhaps the well-docu-
mented cognitive deficits and impairment in global func-
tioning associated with established illness can be
significantly lessened [16-18] and mortality reduced
[19,20].
It also follows that the earlier in the course one treats, the
better the probability of a good response given less com-
plications such as substance use and a sparing of the nerv-
ous system to the exposure of acute illness [21]. We have
previously published observations suggesting that early in
the course of illness bipolar patients can be successfully
maintained on monotherapy [22]. Given the strong asso-
ciation between relapse and/or recurrence and medication
non-adherence [23], the use of monotherapy as opposed
to a combination of medications, may prove to be an
important factor in improving adherence, increasing
response and protecting against potential adverse effects
of polypharmacy such as drug interactions.
The current manuscript describes the key findings from a
48-week open prospective study of the effectiveness and
tolerability of quetiapine monotherapy in a consecutively
recruited series of adolescent patients meeting DSM-IV cri-
teria for bipolar disorder and in whom maintenance treat-
ment to prevent relapse and recurrence was clinically
indicated. We were interested in studying quetiapine
given the more favourable side effect profile among the
available atypical antipsychotic agents indicated for treat-
ment in bipolar disorder at the time of this research. In
addition, quetiapine has been shown to be an effective
agent in treating bipolar depression [24-27], and depres-
sion may account for a substantial proportion of morbid-
ity early in the course of bipolar illness [28]. Based on our
clinical experience, it was our apriori hypothesis that with
the combination of specialist care and adequate quetiap-
ine titration the majority of these bipolar youth would
remain free from relapse or recurrence of a major mood
episode.
Methods
Patient Subjects
Subjects for this study were identified through referrals to
a tertiary care outpatient clinical research program. All
subjects were between 13 to 20 years of age at the time of
recruitment and met DSM-IV lifetime diagnostic criteria
for bipolar disorder on the basis of KSADS-PL interviews
conducted by a child and adolescent psychiatrist. Eligible
lifetime bipolar disorder diagnoses included: bipolar I,
bipolar II, and bipolar nos. The latter diagnosis was given
to subjects who met full diagnostic criteria for hypomania
except for the duration criteria. All diagnoses were
reviewed on a blind consensus basis by at least two addi-
tional research psychiatrists using all available clinical
information.
Patient Inclusion Criteria
Eligible study subjects met DSM-IV lifetime criteria for
bipolar disorder and age criteria (as described above). As
this was a study of maintenance effectiveness, subjects had
to be clinically stable based on assessment by one of the
research psychiatrists (PG, RM, AD), as well as a Clinical
Global Impression Severity (CGI-S) score of 3 or less for a
minimum of 4 consecutive weeks. Other criteria included:
ability to understand and comply with the study require-
ments, and a reliable method of contraception for men-
struating and sexually active females.
Patient Exclusion Criteria
Criteria for study exclusion included: known intolerance
to or prior failure to respond to quetiapine, pregnancy or
lactation, substance dependence within 3 months of
enrolment, medical conditions that would affect absorp-
tion, metabolism or excretion of the study drug, inability
to comply with the study protocol.
Control Subjects
Consenting subjects participating as controls in an ongo-
ing high-risk study [28] were enrolled in the current study
as an age and sex-matched comparison for certain out-
comes including weight and body mass index (BMI) and
for performance and practice effects on repeated neuro-
cognitive testing. Eligible control subjects had no lifetime
history of any major psychiatric disorder based on
KSADS-PL interviews by a child and adolescent psychia-BMC Psychiatry 2009, 9:4 http://www.biomedcentral.com/1471-244X/9/4
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trist. They were not taking any psychotropic medications.
Furthermore, there was no lifetime history of psycho-
tropic medication use, substance abuse or use of pre-
scribed medications that might interfere with
neurocognitive test performance.
Ethical issues
This study was approved by the Royal Ottawa Hospital
Research Ethics Board, the McGill University Institutional
Review Board and an independent Institutional Review
Board. It was also approved by Health Canada. It was
therefore performed in accordance with the ethical stand-
ards laid down in the 1964 Declaration of Helsinki. All
subjects gave informed consent and signed approved con-
sent forms. For under age subjects assent was obtained
along with the requisite consent from a responsible par-
ent.
Open Prospective Flexible Dose Trial of Quetiapine 
Monotherapy
Study patients entered an 8-week titration and wash-out
phase during which quetiapine was titrated against clini-
cal symptoms in increments of 50 mg daily to a maximum
of 800 mg/day in divided or single bedtime doses. At the
same time, any other psychotropic medications were
weaned and if possible discontinued. After the initial 8-
week titration phase, quetiapine was continued to a max-
imum of an additional 40 weeks. In the event of clinically
significant persistent symptoms, side effects, hospitaliza-
tion or a mood episode recurrence, the clinician had sev-
eral options in collaboration with the patient and their
family: to further titrate the dose of quetiapine, to add an
additional psychotropic medication (lithium, anticonvul-
sant, antidepressant, anxiolytic) or to discontinue the
quetiapine completely.
Scheduled study visits were weekly for the first 8 weeks
(V1–V8) and then at least monthly for the duration of the
study (V9–V18). Subjects could come for more frequent
study visits if clinically indicated or requested by the
patient and/or their family. At each study visit the research
psychiatrist completed the Young Mania Rating Scale
(YMRS), Montgomery Asperg Depression Rating Scale
(MADRS), CGI-S, Clinical Global Assessment Scale
(CGAS) and the Affective Morbidity Index (AMI).
Medications allowed throughout the study without being
considered as combination treatment included: up to 2
mg of clonazepam or up to 10 mg of zopiclone per day for
sleep. Antidepressants used in therapeutic doses for longer
than 8 consecutive weeks at anytime through the study
period were counted as combination treatment. In this
study there was no patient who received an antidepressant
for less than 8 consecutive weeks. Treatment compliance
was assessed by direct questioning at study visits and by
tracking pill counts of returned unused medications.
There was no formal psychological intervention for the
duration of the study, however patients received specialist
treatment as usual at each study visit (psychoeducation,
review of residual and/or new symptoms, tolerability and
non-manualized support and problem-solving).
Neurocognitive Testing
Patient and matched control subjects completed neuro-
cognitive tests representing the most reliable findings in
euthymic bipolar patients, namely measures of early
information processing and hippocampal-dependent
memory. These tests included: Visual Backward Masking
(VBM) [29,30], and the California Verbal Learning Test
(CVLT) [31,32]. Neurocognitive testing was repeated for
each subject at enrolment, 12, 24 and 48 weeks.
Laboratory Measures
Laboratory measures (chemistry, hematology, thyroid
function) were taken for patient subjects at enrolment, V8
and V18. Any abnormal results were followed up as med-
ically indicated (see below). A 12-lead ECG was taken at
enrolment and at study completion. Both control and
patient subjects had height and weight recorded at study
visits.
Statistical Analyses
A Chi-square analysis was used to assess the primary
dependent variable: the number of participants success-
fully maintained on quetiapine monotherapy. Split-plot
repeated-measures ANOVA (LOCF data) was used to
assess changes in secondary outcome variables (YMRS,
MADRS, CGI-S, CGAS) with time (VE, V2, V5, V8, V9,
V12, V15, & V18) as the within subject variable and treat-
ment group (monotherapy vs combination therapy) as
the between subject variable. Repeated a priori within-sub-
jects contrasts were used to determine where changes
occurred over time.
For neurocognitive variables, analyses were carried out
using matched pairs, split-plot repeated measures
ANOVA. Study visit was the within subject variable and
study group (patient vs control) was the between subjects
variable. Subjects in the patient group were matched with
controls for age and gender.
To assess the effect of quetiapine on weight and BMI
change we used a matched-pairs, split-plot repeated meas-
ures ANOVA (LOCF data), with time (VE, V9, V12, V18)
as the within subjects variable and study group (patients
vs controls) as the between subjects variable.BMC Psychiatry 2009, 9:4 http://www.biomedcentral.com/1471-244X/9/4
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Results
Study sample description
Twenty-one patients were enrolled in the study. Three
patients dropped out of the study at V11, V12 and V14,
respectively. All drop-out patients were female and being
treated with quetiapine monotherapy at the time. These
patients were similar to the study completers with regard
to age, duration of illness and average daily dose of med-
ication. Reasons for dropping out included: inconven-
ience of study protocol (n = 2) and refusal to continue any
psychotropic medication (n = 1). Drop-out was not asso-
ciated with episode recurrence or adverse effects of the
medication.
The 18 patient subjects completing are described in Table
1. The age of onset in this study was defined as the age of
the first diagnosable mood episode (depression nos,
major depression, hypomania or mania/mixed). Gener-
ally these patients were in their mid to late adolescence at
enrolment and had experienced several years of illness,
mostly depressive in polarity. For example, 83% of sub-
jects began their illness with a depressive episode and in
33% their most recent episode was depressive. For 4 of the
subjects the most recent episode was their index episode;
3 subjects had a mixed or manic episode and 1 subject had
a psychotic major depressive episode. More than half of
the subjects had experienced psychotic features in their
lifetime and the vast majority had a non-remitting
(chronic, chronic fluctuating or partial remission with sig-
nificant residual symptoms) course of illness not meeting
DSM-IV criteria full clinical remission. Of the 18 compl-
eters, 9 subjects had been started on quetiapine acutely
and this was then continued at enrolment into the study,
while 9 patients had been stabilized on other agents that
were weaned over the titration phase: 2 patients were
weaned from lithium, 3 patients were weaned from olan-
zapine, 2 were weaned from an antidepressant and anti-
convulsant combination, while the final 2 subjects were
weaned from antidepressants, although lamotrigine was
continued (see below).
Primary Outcome
Thirteen of the 18 completing patients were successfully
maintained of quetiapine monotherapy (χ2 = 3.56, p =
0.06) for the duration of the maintenance study. Five
patients required combination therapy to treat persistent
or recurring clinical symptoms, although there were no
full-blown recurrences; that is, no patient in this study
completely failed to benefit from quetiapine mono-
therapy. Of the patients requiring adjunctive medication,
2 patients were unable to be weaned during the wash-out
phase from lamotrigine and continued on this combina-
tion, while a third patient had lamotrigine added at week
28 (V13); all for treatment of mood lability and general-
ized anxiety symptoms. Two subjects required the addi-
tion of an antidepressant for treatment of depressive
symptoms starting from week 12 (V9) and week 20 (V11),
respectively. There was no difference in the mean daily
dose of quetiapine between patients maintained on mon-
otherapy compared to those requiring combination ther-
apy (314 mg ± 264 vs 411 mg ± 328, respectively). There
was no difference between treatment groups in gender,
bipolar diagnosis or lifetime comorbidity.
Supporting the clinical observations, the CGI-S scores
declined over the duration of the study (F = 3.44, p < 0.01)
with a significant decrease occurring in the first two weeks
of the study (F = 6.03, P < 0.05). There was no difference
in CGI-S scores between treatment groups (monotherapy
vs combination therapy) and no interactive effect with
time. All completing subjects had CGI-S scores of 3 or less
over the majority of the maintenance phase (Table 2).
Secondary Outcomes
Secondary clinical outcomes included the degree of resid-
ual symptoms and the degree of functional recovery as
measured by MADRS, YMRS, AMI and CGAS scores,
respectively (Table 2). Examination of AMI scores
revealed that there was no effect of treatment group or
Table 1: A description of the 18 patient subjects completing the 
study
Patients (n = 18)
Gender (M:F) 8:10
Age at recruitment (years) 17.7 (1.9)
Age of onset (years) 13.9 (3.0)
Polarity of index episode (%) d, D, m, M 61, 22, 0, 17
Duration of illness (years) 3.4 (2.7)
Most recent mood episode (%) D, m, M 33, 45, 22
Bipolar Diagnosis (%)
BPI 22
BPII 11
BPNOS 67
Lifetime Psychotic Features (%) 61
Hospitalization Ever (%) 44
Clinical Course (%)
Episodic 11
Non-Episodic 89
Comorbid Disorders (%)
Anxiety 33
ADHD 22
Sleep 17
None 22
Mean quetiapine dose over the study (SD) 340.9 mg (276.5)
Mean quetiapine dose at study end (SD) 294.6 mg (267.3)
d refers to minor depression, D to major depression, m to hypomania 
and M to either Manic or mixed episodeBMC Psychiatry 2009, 9:4 http://www.biomedcentral.com/1471-244X/9/4
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interaction between treatment group and time. AMI scores
did significantly decrease over time (F = 3.83, df = 7, 112;
p < .01), primarily between enrolment and the first two
weeks of the study (F = 4.77, df = 1, 16; p < .01).
The MADRS also decreased significantly over time (F =
3.96, df = 7, 112; p < .01), again primarily in the first two
study weeks (F = 14.43, df = 1, 16; p < .01). There were no
effect of treatment group either alone or in interaction
with time. Scores on the YMRS remained low and
unchanged over the course of the study and they did not
differ as a function of treatment group or the interaction
between treatment group and time.
CGI-I scores significantly improved over time (F = 2.48, df
= 7, 112; p < .05), and there was no difference in these
scores as a function of treatment group. A significant inter-
action between time and treatment group (F = 3.78, df =
7,112; p < .01) suggests that this improvement occurred
more rapidly in the monotherapy compared to the com-
bination group. Finally, there was a significant increase in
CGAS scores over time (F = 2.42, df = 7, 112; p < .05).
There was no effect of treatment group or interaction
between treatment group and time on CGAS scores.
Neurocognitive Performance
In addition to clinical measures, we assessed the neuro-
cognitive performance of patients in the study over the
course of the treatment V0, V8, V12 & V18 and compared
this to age and sex matched controls. We wanted to know
if there were any detectable deficits that changed over the
maintenance treatment. By comparing performance of
patients to matched control subjects, we were able to
determine if the neurocognitive performance of patients
differed from individuals who were not ill and not taking
Table 2: Means (SD) of secondary outcome variables as a function of study visit and treatment group.
Treatment Group Study Visit
VE V2 V5 V8 V9 V12 V15 V18
CGI-S
Combination 1.80
(0.84)
1.40
(0.55)
1.60
(0.55)
1.20
(0.45)
1.80
(0.45)
1.60
(0.55)
1.40
(0.55)
1.40
(0.55)
Monotherapy 2.46
(0.66)
1.92
(0.86)
1.46
(0.66)
1.54
(0.66)
1.38
(0.65)
1.46
(0.52)
1.54
(0.66)
1.38
(0.51)
Total 2.28
(0.75)
1.78
(0.81)
1.50
(0.62)
1.44
(0.62)
1.50
(0.62)
1.50
(0.51)
1.50
(0.62)
1.39
(0.50)
CGAS
Combination 79.20
(2.39)
83.00
(2.74)
81.00
(5.47)
82.00
(5.70)
79.00
(2.24)
80.00
(6.12)
83.00
(4.47)
84.00
(2.24)
Monotherapy 73.54
(8.23)
78.84
(7.68)
79.23
(7.86)
80.38
(7.21)
82.38
(8.30)
83.46
(3.15)
82.69
(6.33)
82.38
(3.84)
Total 75.11
(7.48)
80.00
(6.85)
79.72
(7.16)
80.83
(6.69)
81.44
(7.22)
82.50
(4.28)
82.77
(5.74)
82.83
(3.48)
MADRS
Combination 9.40
(6.15)
4.40
(2.88)
4.20
(4.08)
4.80
(4.76)
6.60
(3.91)
5.60
(2.88)
3.00
(3.00)
2.80
(2.28)
Monotherapy 9.15
(6.01)
5.54
(6.03)
3.85
(4.27)
4.54
(3.62)
3.15
(3.55)
3.92
(3.01)
3.46
(3.30)
4.15
(3.84)
Total 9.22
(5.86)
5.22
(5.28)
3.94
(4.10)
4.61
(3.82)
4.11
(3.87)
4.39
(2.99)
3.33
(3.14)
3.78
(3.47)
YMRS
Combination 0.60
(1.34)
0.20
(0.45)
2.20
(3.35)
1.40
(1.67)
2.40
(3.78)
0.40
(0.55)
0.40
(0.89)
0.80
(0.84)
Monotherapy 1.92
(3.04)
1.08
(1.04)
0.77
(1.69)
1.31
(2.06)
0.85
(1.57)
1.31
(1.84)
1.00
(2.24)
1.54
(2.11)
Total 1.56
(2.71)
0.83
(0.98)
1.17
(2.25)
1.33
(1.91)
1.28
(2.37)
1.06
(1.62)
0.83
(1.94)
1.33
(1.84)
CGI-S – Clinical Global Impression Severity
CGAS – Clinical Global Assessment Scale
MADRS – Montgomery Asperg Depression Rating Scale
YMRS – Young Mania Rating ScaleBMC Psychiatry 2009, 9:4 http://www.biomedcentral.com/1471-244X/9/4
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medication and we were able to control for practice effects
of repeated testing.
CVLT Analyses
Analysis of the mean score of immediate free recall (5 tri-
als per study visit) showed no effects of study group
(patients vs controls) or interaction with time (Figure 1).
There was a significant main effect of time (F = 9.66, df =
3, 36; p < .01) with an increase in performance in both
patient and control subjects between V8 and V12 (F =
11.23, df = 1, 12; p < .05). There were no significant effects
of study group, time or their interaction on interference
List B learning. There were no effects of study group on
short-delay free recall and short-delay cued recall or an
interaction between study group (patients vs controls)
and time. Repeated contrasts on the significant effect of
time for short-delay cued recall revealed that both groups
significantly improved their performance between V8 and
V12 (F = 6.97, df = 1, 12; p < .05). A similar pattern of
results were obtained for long-delay recall. Analyses of the
recognition data showed that hits and false alarms did not
differ as a function of study group, time or their interac-
tion.
VBM Analyses
Analysis of reaction times showed no effects of study
group (patients vs controls) or interaction between time
and study group. As expected, there was a main effect for
ISI (F = 168.57, df = 5, 75; p < .01) suggesting that reaction
times became shorter as the ISI increased (task became
easier). This is qualified by an interaction between time of
test and ISI (F = 4.39, df = 15, 225; p < .01) illustrating that
with repeated testing, improvement in reaction times were
greater at shorter ISIs. There was no interaction between
ISI and study group or between time, ISI and study group,
illustrating that the interaction between time and ISI did
not differ as a function of whether participants were
patients or controls.
Analysis of the error rates showed a similar pattern of
results. There were no main effects of study group
(patients vs controls) or time or interactions between time
and study group. There was a main effect of ISI in the
expected direction (F = 49.38, df = 5, 75; p < .01) demon-
strating that error rates increased as ISIs decreased (task
became more difficult). Again, there was an interaction
between time and ISI (F = 2.43, df = 15, 225; p < .01),
illustrating that with repeated testing, error rates
decreased more for shorter ISIs for both patients and con-
trols (Figure 1a and 1b).
Tolerability
No patient discontinued this study because of a lack of
tolerability. No patient experienced a serious life threaten-
ing adverse event. The most commonly reported adverse
events were mild and often transient complaints and there
was no difference in the frequency of adverse events
between monotherapy and combined therapy treatment
groups (Table 3).
Laboratory Measures
All patients had normal prolactin, thyroid, liver functions
and ECG recordings over the course of the study. Four
patients had abnormalities in their lipid profiles during
the study; 1 patient had elevated triglycerides at study
enrolment that normalized by study completion despite
an increase in quetiapine daily dose. Two patients had
mildly elevated fasting cholesterol at V8 that normalized
a. California Verbal Learning Test (CVLT) Mean Immediate Free Recall collapsed across trials (1–5) as a function of time and  treatment condition Figure 1
a. California Verbal Learning Test (CVLT) Mean Immediate Free Recall collapsed across trials (1–5) as a func-
tion of time and treatment condition. There was no difference in scores on the CVLT between subject groups (patients 
compared to controls) on immediate free recall averaged over 5 trials over the course of the study (48 weeks). b. Visual Back-
ward Masking (VBM) Performance at 14 millisecond inter-stimulus interval as a function of time and treatment condition. 
There was no difference in error rates at the hardest level of the VBM task (shortest inter-stimulus interval) between subject 
groups (patients compared to controls) over the course of the study (48 weeks).
0
01 2 2 4 4 8
10
20
30
40
50
60
70
Treatment (n=13)
Control (n=13)
Mean
t-score
Time (weeks)
0
5
10
15
20
25
01 2 2 4 4 8
Treatment (n=16)
Control (n=16)
Errors (%)
Time (weeks)BMC Psychiatry 2009, 9:4 http://www.biomedcentral.com/1471-244X/9/4
Page 7 of 10
(page number not for citation purposes)
by the end of the study. The final patient had elevated fast-
ing cholesterol/HDL ratio at study enrolment that per-
sisted at the end of the study despite a significant decrease
in quetiapine daily dose.
Five patients were monitored for non-clinically significant
neutropenia (< 2.0 × 109 cells/L). All cases with one excep-
tion were transient, resolving by the end of the study (Fig-
ure 2). While there was no statistically significant
relationship between dose of quetiapine and neutropenia,
in all cases the subjects were either on higher doses of
quetiapine (mean 800 mg) or taking an anticonvulsant in
combination with quetiapine. The persistent case of non-
clinically significant neutropenia occurred in a subject
who required adjunctive lamotrigine and 800 mg of
quetiapine for maintenance of a good quality of remission
(could not be weaned from either agent or decreased in
dose).
Weight
Analyses illustrated that neither weight nor BMI changed
over time or as a function of treatment group (patients vs
controls) or their interaction. Furthermore, neither
change in weight or BMI were related to endpoint (V18)
dose or to mean daily dose throughout the study.
When significant weight change was defined as a weight at
study end (V18) of greater or equal to 5 kg or 7% of enrol-
ment weight (VE), 9 patients met this criteria; 6 showing
a significant weight gain and 3 showing a significant
weight loss. Of those that gained weight, 5 were on
quetiapine monotherapy and 1 was on combination ther-
apy. Examination of the data from subjects who gained
weight suggests that it started to occur at the beginning of
the maintenance phase (V8) and continued gradually for
the remainder of the study. However, this pattern was not
different from the weight change shown by control sub-
jects; that is 7 control subjects met this weight change cri-
Table 3: Reported adverse events.
Adverse event Monotherapy
(n = 13)
Combination therapy
(n = 5)
Somnolence 4 2
Dizziness 0 2
Headaches 1 0
Flu-like symptoms 2 1
Absolute neutrophil counts for neutropenic patients over the course of the study in cells × 109/litre Figure 2
Absolute neutrophil counts for neutropenic patients over the course of the study in cells × 109/litre. The absolute 
neutrophil counts for patients who met criteria for neutropenia based on laboratory monitoring at least once during the 48 
week study are plotted. Neutropenia was defined as < 2.0 × 109 cells/litre.
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teria, with 5 gaining weight and 2 losing weight over the
course of the study.
Adherence
Compliance was determined by comparing the dosage
prescribed to the dosage returned. On average, patients
took 95% ( ± 6%) of their prescribed dose (assessed by
pill count, in mg). Stated another way, out of every 28-day
period, they were compliant for 27 days ( ± 2 days). Com-
pliance was unrelated to mean daily dose and to whether
patients were maintained on monotherapy.
Discussion
To our knowledge, this is the first published study investi-
gating the long-term effectiveness and tolerability of
quetiapine monotherapy in adolescent patients diag-
nosed with bipolar disorder. The findings from this study
suggest that quetiapine is an effective maintenance medi-
cation for at least some adolescent patients and is gener-
ally well tolerated. The majority of patients completed the
48-week study and were successfully maintained in very
good quality remission.
There is some evidence in both adults, and more recently
in adolescent bipolar patients, that treatment response
may be selective [33]. This study included patients whose
illness was primarily characterized by a non-episodic
course. Specifically, prior to maintenance treatment, these
subjects manifest significant residual symptoms during
remission including depressive and anxiety symptoms. A
substantial number of patients in this study experienced
psychotic symptoms. Taken together, these patients did
not have the clinical profile of patients known to respond
well and to tolerate maintenance treatment with lithium
[34]. This suggests that adolescent patients suffering from
a non-fully remitting bipolar disorder associated with psy-
chotic features, who require maintenance treatment, may
benefit from quetiapine. In addition, given the nature of
the residual and recurring symptoms, supported by the
improvement in MADRS scores over the initial period of
the maintenance trial, effective treatment of residual
depressive symptoms may be important to a sustained
and good quality of remission.
The very good quality of remission in these patients, as
evidenced by high global functioning scores, low symp-
tom rating scores and supported by neurocognitive test
performance comparable to matched controls, cannot be
attributed to mild illness. Despite a number of subjects
meeting lifetime diagnostic criteria for bipolar disorder
nos based on brief but full-blown hypomanic episodes,
the depression in these subjects was severe and not
uncommonly associated with psychotic features. In addi-
tion these subjects were identified through consultation
requests to a specialized adolescent mood disorders pro-
gram. The observed good quality of remission may have
been associated with a number of factors: These patients
were seen often and followed closely by highly trained
professionals in a specialty setting and medication adjust-
ments were made to maximize therapeutic effect and min-
imize any side effects. In addition, adherence was
extraordinarily high in this study, which again promoted
remission and may have reflected the flexible and intense
follow-up schedule.
The medication was well tolerated and there were no seri-
ous adverse effects. However, the finding of non-clinically
significant neutropenia on routine laboratory testing war-
rants further study. Had these subjects not been participat-
ing in a research study, this laboratory result would likely
not have come to light. It appeared to occur in subjects
who had high doses of quetiapine or quetiapine in com-
bination with an anticonvulsant. Either titration down of
the quetiapine dose or weaning of the anticonvulsant was
associated with normalization of the neutrophil count.
However, the simple passage of time might also be associ-
ated with the normalization and cannot be ruled out. This
finding has been raised by others [35,36], emphasizing
the need to identify subjects at risk for neutropenia who
might benefit from closer monitoring.
Limitations of this study include small numbers of treated
subjects and the fact that treatment was not randomly
assigned and assessed longitudinally in an open non-
blinded fashion. However, the study outcomes were such
that open monitoring should have had no significant
effect on the findings. That is, we studied whether subjects
could be kept in good quality remission on monotherapy
or if they required adjunctive or different medication to
prevent a relapse or recurrence. This is a different outcome
than, for example, percentage of clinical improvement.
Secondly, the numbers of subjects in this study were too
small to complete a more detailed analysis of secondary
outcomes or to demonstrate possible differences between
monotherapy and combined therapy patients. Finally,
while we assume that it was the maintenance treatment
that was responsible for the sustained good quality remis-
sion, we cannot be sure of the longer term outcome unless
these patients are followed prospectively.
Conclusion
In spite of speculation and anecdotal evidence to the con-
trary, this is the second report from our group showing
that adolescent bipolar patients, early in the course of
severe illness, can be maintained in very good remission
on monotherapy [22]. Moreover, the medication when
titrated against symptoms and side effects in a specialized
setting is well tolerated and adherence is very good. Glo-
bal and neurocognitive functioning over the duration of
treatment was comparable to never ill controls. Therefore,BMC Psychiatry 2009, 9:4 http://www.biomedcentral.com/1471-244X/9/4
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it is our speculation that early intervention and follow-up
in a specialty setting are important to the prevention of
burden of illness effects and to morbidity well docu-
mented in patients with established illness. More research
into effective early intervention in this population and the
comparison of long-term benefits and outcomes should
be a priority.
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